OINDPnews


Copley Scientific banner

News

Analyst predicts slight increase in asthma and COPD drug market over next five years

A new report from Transparency Market Research titled "Asthma and COPD Drug Market - Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts, 2010 - 2017" predicts an increase in the asthma and COPD drug market from ~25 billion in 2010 to ~27 billion in 2017. The report suggests that price erosion and the expiration of patents with few novel drugs … [Read more...] about Analyst predicts slight increase in asthma and COPD drug market over next five years

Impel NeuroPharma announces advances in development of pressurized olfactory device

Impel NeuroPharma says that a study has shown that its Pressurized Olfactory Device (POD) was preferred 2 to 1 by testers compared to conventional nasal sprays. POD delivers aerosolized drug, both liquid and powder formulations, to the upper nasal cavity, allowing delivery of therapeutics across the blood-brain barrier, according to Impel. The company says that it … [Read more...] about Impel NeuroPharma announces advances in development of pressurized olfactory device

Bespak MDI valve sales up 12%

Consort Medical has announced record revenue and profits for the year ending April 30, 2012, including a 12% increase in revenue for its Bespak division, which manufactures metered dose inhaler valves and actuators as well as dry powder inhalers. Bespak's operating profit also grew by 17%. According to Consort, the growth in Bespak revenue came about in part due to … [Read more...] about Bespak MDI valve sales up 12%

Savara announces Phase I study results for AeroVanc, funding for Phase 2

Savara Pharmaceuticals has announced positive top-line results from a Phase 1 study of its AeroVanc inhaled dry powder formulation of vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis. According to the company, the study demonstrated that AeroVanc was well tolerated, that clearance of the … [Read more...] about Savara announces Phase I study results for AeroVanc, funding for Phase 2

Pharmaxis submits NDA for Bronchitol, issues update on commercialization in Europe

Pharmaxis has submitted an NDA for Bronchitol inhaled dry powder mannitol for the treatment of cystic fibrosis to the FDA. Pharmaxis CEO Dr Alan Robertson said, “The submission marks the second of two key milestones for the Bronchitol program following approval last month to market the product in Europe. Cystic fibrosis patients have a life‐limiting disease. It … [Read more...] about Pharmaxis submits NDA for Bronchitol, issues update on commercialization in Europe

Alnylam inhaled RSV drug misses primary endpoint in Phase 2b study

Alnylam Pharmaceuticals says that its ALN-RSV01 inhaled RNAi drug failed to meet the primary endpoint of a Phase 2b study, not significantly reducing the incidence of bronchiolitis obliterans syndrome (BOS) at 180 days after infection in lung transplant patients infected with respiratory syncytial virus (RSV) in an “intent-to-treat” (ITTc) analysis, but that it met … [Read more...] about Alnylam inhaled RSV drug misses primary endpoint in Phase 2b study